Posted by Michael Wonder on 03 Oct 2023
Loncastuximab tesirine for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments
3 October 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of loncastuximab tesirine in the NHS in England.
Loncastuximab tesirine is not recommended for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments.
